Clinical Trial: Abiraterone With Dalpiciclib in Salivary Gland Carcinoma

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815522) titled 'Abiraterone With Dalpiciclib in Salivary Gland Carcinoma' on Sept. 08.

Brief Summary: This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of abiraterone combined with dalpiciclib in recurrent/metastatic salivary gland carcinoma patients with AR positive and Her-2 negative. The participants would receive abiraterone combined with dalpiciclib until termination criteria are met.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Salivary Gland Carcinoma

Intervention: DRUG: abiraterone combined with dalpiciclib

The dosing regimen for abiraterone comb...